Discontinued — last reported Q4 '24
Products & Services · Intangible assets
Zerbaxa — Intangible assets
Merck & Co. Zerbaxa — Intangible assets decreased by 21.9% to $260.00M in Q4 2024 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ4 2023
Last reportedQ4 2024
Rolls up toIntangible assets — net
How to read this metric
An increase suggests ongoing investment or acquisition of rights, while a decrease often indicates amortization or potential impairment of the asset's future economic value.
Detailed definition
This metric represents the carrying value of intangible assets specifically associated with the Zerbaxa product line, in...
Peer comparison
Comparable to capitalized R&D or acquired product rights found in the intangible asset schedules of other pharmaceutical companies with specialized antibiotic or therapeutic portfolios.
Metric ID:
mrk_segment_zerbaxa_intangible_assetsHistorical Data
2 periods
| Q4 '23 | Q4 '24 | |
|---|---|---|
| Value | $333.00M | $260.00M |
| QoQ Change | — | -21.9% |
| YoY Change | — | -21.9% |
Range$260.00M – $333.00M
Avg YoY Growth-21.9%
Median YoY Growth-21.9%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s zerbaxa — intangible assets?
- Merck & Co. (MRK) reported zerbaxa — intangible assets of $260.00M in Q4 2024.
- What does zerbaxa — intangible assets mean?
- The total book value of intellectual property and intangible rights specifically tied to the Zerbaxa product line.